Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth D Friedman

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Thrombosis and Haemostasis|July 23, 2004
Lepirudin prevents lethal effects of Shiga toxin in a canine modelThomas Raife, Kenneth D Friedman, Brad Fenwick
Blood|November 13, 2023
How I diagnose and treat thrombocytopenia in geriatric patientsPatrick Foy, Kenneth D Friedman, Laura C Michaelis
Transfusion|January 11, 2012
Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand diseaseMelissa Cushing, Kathy Kawaguchi, Kenneth D Friedman, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 10, 2019
In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand FactorMeaghan E Colling, Kenneth D Friedman, Walter H Dzik
International Journal of Hematology|September 13, 2014
Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2NJohn N Allan, Kenneth D Friedman, Maria T DeSancho
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|October 22, 2016
Differentiation of pernicious anemia from thrombotic thrombocytopenic purpura: The clinical value of subtle pathologic findingsDaniel W Abbott, Kenneth D Friedman, Matthew S Karafin
Transfusion|January 10, 2006
The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasmaThomas J Raife, Kenneth D Friedman, Denis M Dwyre
Thrombosis Research|November 30, 2004
A prothrombotic phenotype in the Copenhagen rat strainBrian C Cooley, Chao-Ying Chen, Kenneth D Friedman, et al.
Journal of Clinical Apheresis|April 5, 2011
Hematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathyNoelle I Samia, Kenneth D Friedman, Jerome L Gottschall, et al.
Transfusion|August 25, 2017
Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathyNarendranath Epperla, Kathleen Hemauer, Mehdi Hamadani, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Thrombosis and Haemostasis|July 23, 2004
Lepirudin prevents lethal effects of Shiga toxin in a canine modelThomas Raife, Kenneth D Friedman, Brad Fenwick
Blood|November 13, 2023
How I diagnose and treat thrombocytopenia in geriatric patientsPatrick Foy, Kenneth D Friedman, Laura C Michaelis
Transfusion|January 11, 2012
Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand diseaseMelissa Cushing, Kathy Kawaguchi, Kenneth D Friedman, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 10, 2019
In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand FactorMeaghan E Colling, Kenneth D Friedman, Walter H Dzik
International Journal of Hematology|September 13, 2014
Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2NJohn N Allan, Kenneth D Friedman, Maria T DeSancho
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|October 22, 2016
Differentiation of pernicious anemia from thrombotic thrombocytopenic purpura: The clinical value of subtle pathologic findingsDaniel W Abbott, Kenneth D Friedman, Matthew S Karafin
Transfusion|January 10, 2006
The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasmaThomas J Raife, Kenneth D Friedman, Denis M Dwyre
Thrombosis Research|November 30, 2004
A prothrombotic phenotype in the Copenhagen rat strainBrian C Cooley, Chao-Ying Chen, Kenneth D Friedman, et al.
Journal of Clinical Apheresis|April 5, 2011
Hematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathyNoelle I Samia, Kenneth D Friedman, Jerome L Gottschall, et al.
Transfusion|August 25, 2017
Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathyNarendranath Epperla, Kathleen Hemauer, Mehdi Hamadani, et al.
Pageof 5